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Design of Bacillus anthracis Lethal Factor Protein Inhibitor Through 
Structure-Based Design
I. Abstract
The isoxazole core of GPHR-00194983 was used as a starting 
point for the design process. This core was tested with 
different side chains to see how they would fit into the active 
site. It was observed that an isoxazole ring with a dimethyl 
ether side chain coordinates with the zinc atom via the 
isoxazole nitrogen and the ether oxygen. Further testing 
showed that an imidazole ring bound more consistently in 
this orientation than the isoxazole core. This core would 
further be modified with an “R1” group directly attached to 
the core, and an “R2” group attached to the terminal methyl 
group.
In order to design a new inhibitor against LF, a structure-
based design was used. GPHR-00194983 was used as a starting 
point since it was previously identified as an inhibitor of LF from 
a library of approximately 230,000;2 however, due to its 
solubility, it was difficult to perform co-crystallization studies 
with LF. For this reason, a new compound had to be 
designed and synthesized, hopefully with improved 
solubility, more favorable pharmacokinetic profiles and 
similar affinity for the LF active site. Using the isoxazole 
core of GPHR-00194983 as a starting point, different parts 
of the molecule could be designed to interact with each 
pocket of the active site, as well as the catalytic zinc 
atom. By optimizing the interactions between the designed 
compounds and each pocket within the active site 
individually, we hoped to design a molecule with better 
binding and solubility than GPHR-00194983. Compounds 
were docked into the LF active site (PDB:1YQY)3 using Glide 
in Maestro.4,5
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II. Objective
III. Optimization of the Core
IV. Optimization of “R1”
The R1 group was designed to interact with the S1’ pocket. 
First, a variety of substituents were tested, varying from 
halogens to ethers to hydrophobic groups. It was 
determined that the hydrophobic groups participated in 
beneficial interactions with the pocket and docked into the 
S1’ pocket consistently. It was thought that these 
hydrophobic groups were the best fit, but later tests 
included amine groups in order to test hydrogen bonding. 
These experiments showed that the amino acids near the 
S1’ pocket were able to accept hydrogen bonds. This meant 
that a terminal amine group included in the R1 was 
predicted to have equal or higher affinity than the strictly 
hydrophobic groups.
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VII. Future Work
Future work includes finishing the optimization of the 
designed compounds. After this, we plan on synthesizing  
some of the compounds and testing their inhibition against 
LF. Eventually, once a compound with biological activity 
against LF is found, co-crystallization studies will be 
performed.  
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Anthrax is an infection caused by Bacillus anthracis, a 
bacterial species that produces a deadly toxin.
During this iterative design process, the structural 
components of our compounds were modified to see how 
this affected the affinity of these compounds as predicted 
by Glide. Compounds with more favorable docking scores 
were retained and modified, and compounds with less 
favorable docking scores were discarded. So far, 
optimization of the S1’ pocket and S2 is underway. Here we 
present the compounds designed based upon many rational 
design trials. 
This toxin is composed of three 
proteins: protective antigen (PA), 
edema factor (EF), and lethal 
factor (LF). Currently, there are no 
commercial treatments for anthrax-
induced toxemia. Available 
treatments include antibiotics, 
which are only effective in early 
disease stages and have no effect 
on the toxin once its produced, or 
antibodies, which have their own 
pharmacokinetic liabilities.1 LF is 
the primary target of this study, 
and the goal was to design a 
small-molecule inhibitor using a 
structure-based design.
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V. Optimization of “R2”
The next part of the design process consisted of finding 
a group capable of reaching the S2 pocket of the active 
site. The initial problem with the design of this group 
was that the S2 pocket is far away from where the core 
was predicted to bind. This meant that if the R2 group 
was able to freely rotate, there would be little 
probability that the group would be docked into the 
pocket. To fix this issue, it was determined that a 
bicyclic ring structure would help the compounds reach 
the pocket. Since these rings are constrained, they 
were able to better reach the S2 pocket. We then 
determined that an alkyl chain ending with a terminal 
amine fit well into the pocket since it can act as a 
hydrogen bond donor. Depending on the ring’s 
structure, a carbon chain of 2-3 carbons worked best to 
attach the amine to the bicyclic. Although the bicyclic 
ring systems used during the initial iterations of the 
design process worked well in terms of docking, we 
realized that the resulting compounds were not 
synthetically feasible. The most recent iterations of our 
design consisted of testing different bicyclic rings to 
hopefully find something more synthesizable.
VI. Conclusions 
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Overall, 19 iterations of the rational design process were 
performed. Compounds based upon GPHR-00194983 were 
designed, and their binding poses were modeled using 
Glide. Through our iterative structure-based design 
process, we have designed a library of compounds with 
more favorable docking scores than the original compound. 
At this point in time, the compounds in our library are 
optimized for interactions with the S1’ pocket and the zinc 
atom, and future studies will finish the optimization of the 
S2 pocket. The main goal of this project was to design an 
inhibitor for LF. While the optimization is not finished, 
compounds have been designed that have greater affinity 
for LF than GPHR-00194983. The second goal of this 
project was to synthesize these compounds and determine 
their IC50 values. This objective was not completed since 
the compounds proved to be too difficult to synthesize. The 
project’s time frame ended while the compounds were 
being redesigned for synthesizability. 
